CAR-NK Cell Therapy Platform
Why in news?
The Technology Development Board (TDB), Department of Science & Technology (DST), Government of India, announced financial support for an indigenous CAR‑NK cell therapy platform being developed by East Ocyon Bio Pvt Ltd, Gurgaon.
About CAR-NK Cell Therapy Platform
CAR-NK (Chimeric Antigen Receptor–Natural Killer) cell therapy is an emerging immunotherapy platform designed to harness the natural cytotoxicity of NK cells, engineered with CARs to target specific cancer or infectious disease antigens. Unlike CAR-T therapies, CAR-NK approaches are considered safer, more scalable, and potentially “off-the-shelf,” meaning they don’t require patient-specific customization.
Key Features of CAR-NK Therapy
- Safety: Lower risk of cytokine release syndrome compared to CAR-T.
- Scalability: NK cells can be derived from cord blood, induced pluripotent stem cells (iPSCs), or established cell lines, enabling mass production.
- Versatility: Effective against both hematological malignancies and solid tumors.
- Allogeneic Use: Can be administered across patients without severe graft-versus-host disease risks.
Current Developments in India
- The Technology Development Board (TDB) under India’s Department of Science & Technology has backed East Ocyon Bio Private Limited (Gurgaon) to develop an indigenous CAR-NK platform.
- The project focuses on “off-the-shelf” CAR-NK therapies targeting:
- Treatment-resistant solid tumors
- Leishmaniasis, a neglected tropical disease prevalent in rural India
- This initiative aims to establish India’s first platform-based ecosystem for CAR-NK therapies, strengthening capabilities in advanced immunotherapy and biotherapeutics manufacturing.
CAR-NK vs CAR-T
| Feature |
CAR-NK Therapy |
CAR-T Therapy |
| Source |
NK cells (cord blood, iPSCs, cell lines) |
Patient’s own T cells (autologous) |
| Safety Profile |
Lower risk of cytokine storm |
Higher risk of severe immune reactions |
| Scalability |
Off-the-shelf, mass-producible |
Patient-specific, time-intensive |
| Applications |
Solid tumors + infectious diseases |
Mostly hematological cancers |
| Cost & Accessibility |
Potentially lower, more accessible |
High cost, limited availability |
Implications
- Global Impact: CAR-NK is being explored worldwide as a next-generation immunotherapy.
- India’s Leap: By investing in CAR-NK, India positions itself at the forefront of affordable precision medicine, especially for underserved populations.
- Future Outlook: If successful, CAR-NK could democratize access to advanced cancer and infectious disease treatments.
Download Pdf
